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Francisella tularensis is a highly virulent Gram-negative bacterium and is the etiological agent of the disease
tularemia. IclR, a presumed transcriptional regulator, is required for full virulence of the animal pathogen, F.
tularensis subspecies novicida U112 (53). In this study, we investigated the contribution of IclR to the intra-
cellular growth, virulence, and gene regulation of human pathogenic F. tularensis subspecies. Deletion of iclR
from the live vaccine strain (LVS) and SchuS4 strain of F. tularensis subsp. holarctica and F. tularensis subsp.
tularensis, respectively, did not affect their abilities to replicate within macrophages or epithelial cells. In
contrast to F. tularensis subsp. novicida iclR mutants, LVS and SchuS4 iclR strains were as virulent as their
wild-type parental strains in intranasal inoculation mouse models of tularemia. Furthermore, wild-type LVS
and LVSiclR were equally cytotoxic and induced equivalent levels of interleukin-1 expression by infected
bone marrow-derived macrophages. Microarray analysis revealed that the relative expression of a limited
number of genes differed significantly between LVS wild-type and iclR strains. Interestingly, many of the
identified genes were disrupted in LVS and SchuS4 but not in their corresponding F. tularensis subsp. novicida
U112 homologs. Thus, despite the impact of iclR deletion on gene expression, and in contrast to the effects of
iclR deletion on F. tularensis subsp. novicida virulence, IclR does not contribute significantly to the virulence or
pathogenesis of F. tularensis LVS or SchuS4.
Francisella tularensis is a Gram-negative bacterium and the
etiological agent of tularemia, or “rabbit fever.” While zoonotic
hosts include small mammals, such as rabbits and voles, F. tula-
rensis is also found in ticks, mosquitoes, and flies and can replicate
within amoebae as well (29). Human infection with F. tularensis
can occur by several routes, including bites by arthropod vectors
(4, 5, 34), contact with contaminated tissues, ingestion of contam-
inated food or water (28, 43), or inhalation of aerosolized bacteria
(18, 48). F. tularensis is considered a select agent by the Centers
for Disease Control and Prevention (CDC) due to its low infec-
tious dose (as few as 10 organisms) via the pulmonary route and
its potential as a biological threat agent (15, 46).
There are two F. tularensis subspecies that are most commonly
associated with disease in humans: F. tularensis subsp. tularensis
(type A) and F. tularensis subsp. holarctica (type B). The live
vaccine strain (LVS) of F. tularensis subsp. holarctica is a useful
model for studying the virulent F. tularensis subspecies because it
causes disease in mice, is attenuated in humans (19), and shares
genomic and proteomic similarity with F. tularensis subsp. holarc-
tica and F. tularensis subsp. tularensis (51). F. tularensis subsp.
novicida, which does not cause disease in healthy humans, has
significant similarity with F. tularensis subsp. holarctica and F.
tularensis subsp. tularensis and is also used as model organism for
studying F. tularensis pathogenesis. Although there are reports of
F. tularensis subsp. novicida causing disease, these cases are com-
monly associated with immunocompromised individuals (2, 9, 24,
32). However, F. tularensis subsp. novicida does cause a severe
disease in in vivo mouse models (40).
Francisella is known to predominately infect and replicate
within macrophages but also infects and replicates within neutro-
phils (37), dendritic cells (3), and type II alveolar epithelial cells
(23). After phagocytosis, F. tularensis escapes the phagosome and
replicates within the cytoplasm of host cells (1, 10). Numerous in
vitro and in vivo screens have identified virulence factors required
for this intracellular life cycle (13, 14, 27, 30, 35, 41, 47, 49, 53);
however, many of the identified virulence factors have little or no
similarity to known proteins of other bacteria, and their functions
remain, for the most part, unknown.
Weiss et al. recently identified a locus (FTN_0720) in F.
tularensis subsp. novicida U112 that is important for virulence
in mice as determined by an in vivo competition assay between
a FTN_0720 deletion mutant and wild-type U112 (53).
FTN_0720 encodes a protein with homology to the IclR family
of transcriptional regulators. IclR family members activate and
repress genes in a wide range of bacteria, including genes
involved in sporulation, metabolism, drug efflux pumps and
organic solvent tolerance, and phytopathogenicity (39). Given
the close genetic relationship among the F. tularensis subspe-
cies, the phenotype of the F. tularensis subsp. novicida iclR
deletion strain suggests that IclR may be involved in the patho-
genicity of the F. tularensis subsp. holarctica and F. tularensis
subsp. tularensis subspecies. We investigated the contribution
of IclR homologs in the pathogenicity of F. tularensis subsp.
holarctica and F. tularensis subsp. tularensis by evaluating the
role of IclR in gene expression, host cell interactions, and
virulence of F. tularensis subsp. holarctica LVS (FTL_1364)
and F. tularensis subsp. tularensis SchuS4 (FTT_0748) strains.
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MATERIALS AND METHODS
Bacterial strains. F. tularensis subsp. holarctica LVS was obtained from the
CDC, Atlanta, GA. F. tularensis subsp. tularensis SchuS4 was obtained from BEI
Resources. F. tularensis subsp. novicida U112 was obtained from the American
Type Culture Collection (ATCC). An iclR transposon mutant was one of two
mutants of the transposon mutant library (21) and was received as a gift from
Colin Manoil. All strains were maintained on chocolate agar supplemented with
1% IsoVitaleX (Becton-Dickson), brain heart infusion (BHI) broth supple-
mented with 1% IsoVitaleX, or Chamberlain’s defined medium (CDM) (6).
Escherichia coli TOP10 cells (Invitrogen) were used for cloning purposes. E. coli
was propagated in Luria broth supplemented with hygromycin at 200 g/ml or
kanamycin at 20 g/ml as necessary for antibiotic selection. All cultures were
grown at 37°C.
Cell culture. J774A.1 (ATCC TIB-67) cells are a macrophage-like cell line
derived from mouse sarcoma reticulum cells and were cultured in Dulbecco’s
minimal essential medium (DMEM) with 4.5 g/liter glucose, 10% fetal bovine
serum, and 2 mM L-glutamine. TC-1 (ATCC CRL-2785) cells are a tumor cell
line derived from mouse primary lung epithelial cells and were cultured in RPMI
1640 supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1.5 g/liter
sodium bicarbonate, 10 mM HEPES, and 0.1 mM nonessential amino acids.
Bone marrow-derived macrophages were generated by flushing bone marrow
cells from C57BL/6 mouse femurs, and recovered cells were incubated for 6 days
on 15 cm2 non-tissue culture-treated dishes in L929 cell-conditioned DMEM.
Nonadherent cells were removed by washing with phosphate-buffered saline
(PBS), and bone marrow-derived macrophages were recovered from the dishes
by using 1 mM EDTA in PBS.
Molecular techniques and allelic exchange. For both LVS and SchuS4 the iclR
deletion was generated by splice overlap extension (SOE) PCR using primers
designed to amplify the 5 and 3 regions of the iclR locus, which were then
annealed to their complementary, homologous genomic DNA tags (20, 25). The
subsequent deletion left only the first 6 amino acids and the stop codon of iclR.
Each construct was cloned into the pCR-Blunt II TOPO vector (Invitrogen),
verified by DNA sequence analysis, and subsequently cloned into pMP590 (sacB
Kanr) using BamHI and NotI restriction sites (20, 33). For allelic exchange,
plasmids were electroporated into LVS or SchuS4 and integrants were selected
on chocolate agar containing kanamycin (10 g/ml). Kanr strains were grown
overnight and plated on 10% sucrose for counterselection (loss of plasmid) (20,
33). Both the LVS and SchuS4 iclR deletion strains were confirmed for loss of
iclR by PCR. For complementation of the iclR deletion in LVS, iclR and its
predicted promoter were PCR amplified and subcloned into the pCR-Blunt II
TOPO vector (Invitrogen). After MluI/EcoRV restriction digestion, the con-
struct was ligated into the pMP633 low-copy-number Francisella shuttle vector
(20) and electroporated into LVSiclR. Complementation was determined by
detection of iclR in the complementation strain via PCR as well as demonstration
of increased iclR transcript levels via microarray analysis (data not shown).
Gentamicin protection assays. Gentamicin protection assays were performed
as described previously (20, 23). Briefly, J774A.1 murine macrophages, TC-1
murine lung epithelial cells, or bone marrow-derived macrophages were infected
with LVS or SchuS4 at a multiplicity of infection (MOI) of 100. Cells were
incubated with the bacterial inoculum for 2 h (J774A.1 and bone marrow-derived
macrophages) or 4 h (TC-1) and then incubated with medium containing 25
g/ml gentamicin for an additional 2 h to kill extracellular bacteria. At time
points of 4 h (or 6 h for TC-1) and 24 h, medium was removed and cells were
washed with PBS and then scraped from the dish, and the bacteria were serially
diluted and plated to determine the number of viable bacteria.
Mouse infections. Six- to 8-week-old C57BL/6 mice were anesthetized intra-
peritoneally (i.p.) with avertin and then inoculated intranasally (i.n.) with bac-
teria suspended in 50 l PBS by application to the nares of each mouse or
inoculated intradermally (i.d.) by injection into the tail using the same volume.
Concentrations of LVS and U112 were determined based on Klett units and
concentrations of SchuS4 were determined by using a spectrophotometer (based
on the optical density at 600 nm [OD600]), and inocula were serially diluted and
plated on chocolate agar to confirm the CFU administered. At the designated
time points, mice were euthanized and the lungs, liver, and spleen of each mouse
were removed and homogenized. Serial dilutions of the homogenates were
plated on chocolate agar to enumerate the bacterial organ burdens. Statistical
significance between strains in each organ and at each time point was determined
by the Mann-Whitney nonparametric test using GraphPad Prism v.5 software.
All animal experiments were performed according to the animal care and use
guidelines as established by IACUC-approved protocols.
IL-1 ELISAs and cytotoxicity assays. Bone marrow-derived macrophages
were seeded in 12-well dishes at 1  106 cells per well, infected with bacteria at
an MOI of 500 in a final volume of 1 ml of medium per well, and incubated at
37°C. After 24 h, the supernatants from each well were collected, centrifuged to
pellet cellular debris, and stored at 20°C. The interleukin-1 (IL-1) enzyme-
linked immunosorbent assay (ELISA) was performed using the BD OptEIA
mouse IL-1 ELISA kit (BD Biosciences) according to the manufacturer’s pro-
tocol. The OD450 was read using a TECAN Infinite M200 and analyzed using
Magellan version 6 software. Cytotoxicity assays were performed using the Tox-
iLight BioAssay kit (Lonza) following the manufacturer’s protocol for cytokine
detection from supernatants, and the luminescence was read using a TECAN
Infinite M200 instrument and analyzed using Magellan version 6 software. Sta-
tistical significance between each strain was determined with Student’s t test
using the GraphPad Prism version 5 software.
Microarrays. RNA was obtained using the RiboPure bacteria kit (Ambion)
according to the manufacturer’s protocol. Briefly, bacteria were grown to early
mid-log phase in CDM and pelleted. Cells were disrupted by suspension in
TRIzol and vortexing with 0.1-mm glass beads. Purified RNA was recovered by
chloroform extraction followed by treatment with DNase I to remove DNA.
Microarray analysis was performed following the guidelines provided by the
Venter Institute for Genomic Research (SOPM007; M008). Briefly, aminoallyl
(aa)-labeled cDNA was generated from 2 g total RNA using SuperScript III
reverse transcriptase (Invitrogen), random hexamers, and deoxynucleoside
triphosphates containing aa-UTP. After removal of unincorporated aa-dUTP
and free amines, labeled cDNA was coupled to Cy3 or Cy5 monoreactive dye
(GE Healthcare). The Francisella microarray slides (Pathogen Functional
Genomics Resource Center [PFGRC]) contained 2,331 70-mer oligonucleotides
in quadruplicates of the F. tularensis SchuS4 genome and several LVS genes as
well as quadruplicates of 70-mer oligonucleotides for 500 Arabidopsis thaliana
oligonucleotides as controls. Slides were prehybridized in 5 SSC (1 SSC is
0.15 M NaCl plus 0.015 M sodium citrate), 10% SDS, and 1% bovine serum
albumin, washed, and then hybridized with cDNA probes at 42°C. After post-
hybridization washes, the slides were scanned using the GenePix 4000B scanner
and GenePix Pro version 6.0 software. The microarray data were normalized
using the TIGR program MIDAS version 2.22 and analyzed using the TIGR
Multiexperiment viewer version 4.2.1 (MeV) as part of the TM4 suite software
(45). Using MeV, pooled, normalized Cy5/Cy3 intensities from wild-type LVS
control arrays were compared to pooled, normalized Cy5/Cy3 intensities from
LVS iclR arrays. This list was filtered by statistical significance using the sig-
nificance analysis for microarrays (SAM) provided in MeV after an 80% cutoff
filter and using a false-discovery rate of 5%.
Quantitative RT-PCR. Quantitative reverse transcriptase PCR (RT-PCR) was
performed in a 96-well format using the SensiMix SYBR & Fluorescein one-step
kit (Bioline) following the manufacturer’s protocol. Briefly, 50 ng of RNA iso-
lated from wild-type or iclR mutant strains was mixed with SensiMix SYBR &
Fluorescein, RNase inhibitors, and designated primers in a 20-l volume. A
genomic DNA ladder and a no-RT control were analyzed using the SensiMix
SYBR & Fluorescein kit following the manufacturer’s protocol with primers to
gyrA. Thermocycling and detection were performed using the iCycler thermal
cycler (Bio-Rad). All starting quantity (SQ) values were normalized to the mean
SQ value for gyrA.
Antibiotic sensitivity assays. F. tularensis LVS was grown to mid-log phase in
BHI broth supplemented with 1% IsoVitaleX, the bacterial suspension was
spread onto chocolate agar plates, and antibiotic-containing filter paper discs
were placed in the center of each plate. Rifampin (5 g), tetracycline (30 g),
and colistin (10 g) discs were purchased preloaded from Becton Dickinson. The
ampicillin and polymyxin B discs were self-prepared by adding a 10-l or 20-l
volume of antibiotic per disc with 10 g ampicillin or 20 g polymixin B. Bacteria
were grown for 36 h, and the diameter of the zone of inhibition was measured.
Microarray data accession numbers. The raw and normalized microarray data
are available on the GEO database under the following accession numbers:
GSM574374, GSM574375, GSM574376, GSM574377, GSM574379, GSM574380,
and GSE23454.
RESULTS
Comparison of iclR alleles among F. tularensis subspecies and
construction of iclR deletion mutants. The locus FTL_1364 is
annotated as a hypothetical protein in NCBI; however, some of
its homologs in other Francisella species are annotated as pro-
teins belonging to the IclR family of transcriptional regulators.
A search for conserved domains found within FTL_1364 re-
sulted in several related hits, including a helix-turn-helix
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(HTH) domain conserved among IclR family members. Addi-
tionally, Francisella IclR has a C-terminal domain with high
similarity to the IclR family profile Pfam01614. A recent pub-
lication described a highly specific IclR family member profile
that lies outside the HTH domain and covers less than 100
amino acids in the central region toward the C-terminal end
(31). Those authors classified current Pfam01614 members as
belonging to the IclR family, based on the new profile. Fur-
thermore, BLAST analysis of F. tularensis LVS or SchuS4 IclR
revealed high similarity to IclR family proteins found across
many bacterial species. F. tularensis IclR proteins share con-
siderable amino acid identity (30 to 40%) and amino acid
similarity (60%) with non-Francisella IclR family proteins.
Overall, the bioinformatic analysis strongly suggests that Fran-
cisella FTL_1364 and its homologous loci in other Francisella
species encode a protein belonging to the IclR family of tran-
scriptional regulators.
By using the NCBI and the Francisella genome browser
(www.francisella.org) for annotations and synteny analysis, we
found that the iclR locus has shared characteristics among F.
tularensis subsp. novicida U112, F. tularensis subsp. holarctica
LVS, and F. tularensis subsp. tularensis SchuS4 strains
(FTN_0720, FTL_1364, and FTT_0748, respectively) (Fig.
1A). On one side of iclR in each strain is a gene encoding a
predicted protein with similarity to an esterase lipase
(FTL_1363, FTN_0721, and FTT_0749). On the other side of
FIG. 1. Comparison of iclR in three Francisella strains. (A) Synteny diagram of the genomic organization of the iclR locus in F. tularensis subsp.
novicida U112 (FTN_0720), F. tularensis subsp. holarctica LVS (FTL_1364), and F. tularensis subsp. tularensis SchuS4 (FTT_0748). (B) Amino acid
sequence alignment of F. tularensis subsp. novicida U112, F. tularensis subsp. holarctica LVS, and F. tularensis subsp. tularensis SchuS4 IclR.
Alignment was created using VectorNTI software and iclR sequences uploaded from NCBI annotated genomes of each strain and translated using
VectorNTI. Red letters highlight residues conserved between all three strains. Blue letters highlight the residues conserved between two strains.
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iclR is a gene encoding a predicted protein with similarity to
the multidrug efflux protein EmrA (FTL_1365-66, FTN_0718,
and FTT_0747). One difference is that EmrA is divided into
two ORFs in LVS. There are other differences in the length
and coding sequences of this genetic region, including an ad-
ditional open reading frame in U112 that encodes a predicted
protein of unknown function, FTN_0719. Nevertheless, in each
strain, iclR is located in a similar region of the genome.
Additionally, iclR itself is highly conserved among the three
F. tularensis strains U112, LVS, and SchuS4. SchuS4 iclR has
three nucleotide differences compared to iclR from LVS that
translate into two amino acid differences, S22G and H78Y,
between LVS and SchuS4 IclR. U112 iclR has 95 nucleotide
differences compared to LVS iclR and 94 nucleotide changes
compared to SchuS4 iclR. Although this results in a 3-nucleo-
tide truncation of U112 iclR, there is 80% amino acid identity
between the U112 IclR and the SchuS4 and LVS IclR proteins
(Fig. 1B). While these similarities suggest that IclR is con-
served among the U112, LVS, and SchuS4 strains, there are a
sufficient number of differences to account for possible func-
tional deviations between these strains as well. Due to genetic
similarity and the contribution of IclR to the virulence for F.
tularensis subsp. novicida, we investigated the potential contri-
bution of IclR to the virulence of F. tularensis subsp. holarctica
and F. tularensis subsp. tularensis. To do this, we made a clean
deletion of the iclR gene in the F. tularensis subsp. holarctica
LVS (LVSiclR) and SchuS4 (SchuS4iclR) by using SOE
PCR and allelic exchange in LVS (FTL_1364). We also gen-
erated an iclR complementation strain by expression of iclR on
a low-copy-number shuttle vector.
LVS and SchuS4 iclR deletion mutants are competent for
intracellular replication. One method to assess the contribu-
tion of IclR to F. tularensis virulence is to determine what role
IclR plays in intracellular replication. We used gentamicin
protection assays in the J774A.1 murine macrophage-like cell
line and the TC-1 murine lung epithelial cell-like cell line to
assess intracellular replication by iclR deletion mutant strains.
Both LVS iclR and wild-type LVS replicated approximately 2
logs by 24 h in both J774A.1 and TC-1 cells (Fig. 2A and B).
We also performed these assays in bone marrow-derived mac-
rophages, and both wild-type LVS and LVS iclR replicated
intracellularly in these cells (Fig. 2C). Similarly, the intracel-
lular replication of SchuS4iclR was similar to wild-type
SchuS4 in J774A.1 cells (Fig. 2D). These results demonstrate
that IclR is not required for intracellular replication of LVS or
SchuS4 in these cell types.
LVS iclR is not attenuated following intranasal or intrad-
ermal inoculation of mice. Properties other than intracellular
replication contribute to F. tularensis pathogenesis. We there-
fore determined whether IclR was required for LVS virulence
in vivo. To test this, we used a mouse model of pulmonary
tularemia in which we inoculated C57BL/6 mice i.n. with a
lethal dose (1  105 CFU) of LVS or LVS iclR. At 1, 3, 7, and
8 days postinoculation, the lungs, liver, and spleen were har-
vested to enumerate the bacterial organ burdens (Fig. 3A).
These initial experiments revealed that there were no differ-
ences in the organ burdens at 1 or 3 days postinoculation. At
day 7, there appeared to be slight differences in the organ
burdens in the liver and spleen, and by day 8 the organ burdens
in the liver and spleen had not increased. These initial exper-
iments suggested that LVS iclR may demonstrate enhanced
clearance in the mouse. This would correlate with previously
published data demonstrating a decrease in the competitive
index in the spleen at 48 h for the F. tularensis subsp. novicida
U112 iclR deletion mutant compared to wild-type F. tularensis
subsp. novicida U112 (53).
To further investigate the possibility of a more subtle phe-
notype of enhanced clearance, we used a low-dose (1  103
FIG. 2. Intracellular replication of LVS iclR and SchuS4 iclR in murine macrophages or lung epithelial cells. Gentamicin protection assays were
performed by infecting J774A.1 murine macrophages (A), TC-1 murine lung epithelial cells (B), and bone marrow-derived macrophages (BMMs)
(C) with wild-type LVS or LVS iclR at an MOI of 100. (D) A gentamicin protection assay was performed using J774A.1 cells infected with wild-type
SchuS4 or SchuS4 iclR. Bars represent the standard deviations of three replicate wells, and each graph is representative of two separate experiments.
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CFU) i.n. inoculation of groups of six wild-type C57BL/6 mice
with LVS or LVS iclR. At days 1, 3, 7, and 10 postinoculation,
we again harvested the lungs, liver, and spleen to calculate the
bacterial organ burdens. There were no significant differences
between the bacterial organ burdens of LVS iclR or wild-type
LVS at any time point (Fig. 3B). This suggests that LVS iclR
is not attenuated in a mouse model of pulmonary tularemia.
Since the experiments with the F. tularensis subsp. novicida
U112 iclR deletion mutant were performed using subcutaneous
(s.c.) and i.p. inoculations, we investigated whether the role for
iclR in pathogenesis may be route specific. Groups of six to
seven wild-type C57BL/6 mice were infected i.d. with 3  105
CFU of LVS or LVS iclR. The i.d. route has a comparable
50% lethal dose and is similar in nature to the s.c. route (17).
At 1, 3, and 7 days postinoculation, we again harvested the
lungs, liver, and spleen and determined bacterial organ bur-
dens. At each time point and in each organ, there were no
significant differences in the bacterial burdens between the
LVS and LVS iclR groups (Fig. 3C). These data indicate that
for LVS, iclR is not required for pathogenesis in the mouse via
the i.n. or i.d. route.
SchuS4 iclR is not attenuated following intranasal inocu-
lation of mice. Although iclR does not appear to be required
for LVS pathogenesis, it is possible that iclR plays a role in
SchuS4 pathogenesis. We inoculated groups of four wild-type
C57BL/6 mice i.n. with a lethal dose (100 CFU) of wild-type
SchuS4 or SchuS4 iclR. At 1 and 3 days postinoculation, the
lungs, liver, and spleen were harvested to enumerate the bac-
terial organ burdens of infected mice (Fig. 4). At both time
points and in each organ, there were no differences in bacterial
burden between the wild-type SchuS4 and SchuS4 iclR
groups. These data suggest that IclR does not play a role in the
in vivo virulence of SchuS4 when assessed in the mouse model
of pulmonary tularemia.
An F. tularensis subsp. novicida U112 iclR transposon mu-
tant is attenuated following intranasal inoculation of mice. As
noted above, an iclR deletion mutant in F. tularensis subsp.
novicida U112 displays a decreased competitive index in the
spleen following s.c. or i.p inoculation of mice (53). Therefore,
we wanted to determine whether iclR is required for F. tula-
rensis subsp. novicida U112 pathogenesis in a pulmonary
mouse model. We inoculated groups of six wild-type C57BL/6
FIG. 3. Recovery of LVS iclR mutant in mice following i.n. or i.d. inoculation. (A and B) C57BL/6 mice were inoculated with either wild-type
LVS (circles) or LVS iclR (triangles) i.n. at a lethal dose of 1  105 CFU (A) or a low dose of 1  103 CFU (B). (C) C57BL/6 mice were
inoculated with either wild-type LVS (circles) or LVS iclR (triangles) i.d. at a dose of 3  105 CFU. Each symbol represents data from a single
mouse. There were no significant differences in recovery of mutant versus wild-type organisms from any organ at any time point as determined by
the Mann-Whitney nonparametric test in the low-dose (B) and i.d. (C) experiments.
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mice i.n. with a dose of approximately 10 CFU of wild-type
U112 or a U112 iclR transposon mutant. At 1 and 5 days
postinoculation, the lungs, liver, and spleen were harvested
and the bacterial organ burdens were enumerated. Each organ
had reduced burdens of the iclR transposon mutant compared
to wild-type U112, and at day 5 these differences were statis-
tically significant in the liver and spleen (Fig. 5). These data
suggest that iclR is required for U112 pathogenesis via the i.n.
route and correlate with the previously published data for the
s.c. and i.p. routes.
Deletion of iclR does not affect IL-1 expression or cytotox-
icity of infected cells. To determine if there is an altered cel-
lular response to LVS iclR compared to wild-type LVS, we
measured the production of proinflammatory cytokines by in-
fected cells. Bone marrow-derived macrophages were infected
at an MOI of 500 with LVS or LVS iclR, and the supernatants
were analyzed for IL-1 at 24 h postinfection (Fig. 6A). The
levels of IL-1 measured in the supernatants of LVS iclR-
infected cells were similar to those in cells infected with wild-
type LVS, and no differences between strains were statistically
significant.
F. tularensis has also been reported to induce cytotoxicity of
infected macrophages. To determine whether there was a
change in cytotoxicity induced by LVS iclR, we infected mu-
rine bone marrow-derived macrophages with LVS or LVS
iclR at an MOI of 500 and performed cytotoxicity assays on
supernatants collected at 24 h postinfection. As shown in Fig.
6B, LVS iclR induced cytotoxicity in infected cells to a level
similar to that of wild-type LVS, and no differences between
strains were statistically significant.
Effects of IclR on gene expression. Due to its homology to
transcriptional regulators, we used microarray analysis to de-
termine what genes in LVS were affected by IclR by comparing
gene expression between the LVS iclR mutant and wild-type
LVS. We grew LVS and LVS iclR to mid-log phase to harvest
RNA for reverse transcription and amino-allyl labeling of
cDNA, and the labeled cDNA was hybridized to microarray
FIG. 4. Recovery of the SchuS4 iclR mutant in mice following i.n.
inoculation. C57BL/6 mice were inoculated with either wild-type
SchuS4 (circles) or SchuS4 iclR (triangles) i.n. at a dose of 100
CFU. No differences in recovery of mutant versus wild-type organisms
from any organ at any time point were significant based on the Mann-
Whitney nonparametric test.
FIG. 5. Recovery of the U112 iclR transposon mutant in mice fol-
lowing i.n. inoculation. C57BL/6 mice were inoculated with either
wild-type U112 (circles) or U112 iclR mutant (triangles) i.n. at a dose
of 10 CFU. Differences in recovery of mutant versus wild-type or-
ganisms at day 5 for the liver and spleen were significant based on the
Mann-Whitney nonparametric test.
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slides. The slides are printed for every annotated ORF for
SchuS4, plus LVS alleles that are either not present or are
variant in SchuS4, but the slides are not tailored to F. tularensis
subsp. novicida. Three separate microarrays from independent
RNA samples were pooled, and statistically significant gene
expression differences between LVS iclR and wild-type LVS
were determined by SAM (Table 1). Genes exhibiting signifi-
cant changes in expression are listed by the provided locus
annotations, LVS or SchuS4, as printed on the slides.
Using the above criteria, we identified 13 downregulated and
4 upregulated genes in LVS iclR. The list of genes identified
comprises diverse functional groups, suggesting that IclR does
not impact expression of one specific functional group of pro-
teins. There were several IclR-affected genes annotated as
encoding hypothetical proteins. To get a better idea of what
types of proteins these genes may be encoding and to possibly
obtain insight on IclR function, we performed BLASTp anal-
yses. Many of the proteins were only conserved in Francisella,
with no similarity to proteins or conserved domains in other
bacteria. However, there were several proteins with similarity
to known proteins in other bacteria, and these are described in
Table 1. Although most of the genes were represented exclu-
sively by the SchuS4 allele, there were two cases where the
SchuS4 and LVS homologs were both printed on the microar-
ray slide and also appeared on the gene list as having signifi-
cant expression changes in the absence of IclR. FTT_0741c
and its FTL_1373 homolog were both upregulated in LVS
iclR, and both FTL_0388 and its homolog FTT_0885 were
downregulated in LVS iclR. Overall, although further studies
need to be performed to demonstrate a function of IclR, both
bioinformatic and microarray data suggest that the Francisella
IclR may function as a transcriptional regulator.
Comparison of IclR-affected genes between LVS, SchuS4,
and U112. One explanation for the phenotypic differences ob-
served for iclR mutants among the F. tularensis U112, LVS, and
SchuS4 strains could be differences in the genes affected by
IclR among the strains. To address this we performed a more
detailed examination of the genes on our microarray list. First,
we performed synteny analysis using the genome synteny tool
at www.francisella.org to determine whether each gene was
annotated in SchuS4, LVS, and U112. We observed that there
were a few genes that were not annotated or not present in all
three strains, as shown in Table 1. Second, we generated align-
ments and protein translations of the genes by using Vector
NTI software based on the NCBI annotation or the putative
loci of nonannotated genes from the synteny analysis, if they
were found. For example, sequence alignments revealed that in
LVS there is an unannotated ORF between FTL_1120 and
FTL_1121 that bears homology to FTT_1082. Nearly half of
the genes were similarly annotated and encoded one intact
ORF in SchuS4, LVS, and U112. However, a significant per-
centage of genes displayed considerable sequence differences
between strains, as shown in Table 1.
Of these genes, many were not intact in the virulent strains
LVS and/or SchuS4, whereas the homologous genes in U112
were intact. For example, FTL_1506 and FTL_1507 are pseu-
dogenes because they encode two ORFs, while their SchuS4
(FTT_0723c) and U112 (FTN_0634) genes encode only one
ORF. One special case is FTT0715, which along with its LVS
homolog FTL_1521, has two large deletions, 131 bp (119 bp in
LVS) and 197 bp, compared to the U112 homolog FTN_0627.
The significance of these deletions cannot be inferred, and
although these genes are not pseudogenes, the fact that these
large deletions are present only in SchuS4 and LVS is note-
worthy. This also highlights that many of the intact genes on
the microarray list have greater overall sequence differences
between U112 and LVS or SchuS4 compared to the differences
between LVS and SchuS4.
We next wanted to determine whether the set of genes that
were changed in expression in LVS iclR were also changed in
the absence of IclR in U112. First, we performed quantitative
RT-PCR on six genes that were differentially regulated in the
microarray for LVS versus LVS iclR (Fig. 7A), and we nor-
malized the results to the housekeeping gene gyrA. We also
included iclR. As expected, we detected a dramatic decrease in
iclR transcript in LVS iclR and a negligible change in gyrA. Of
the six genes analyzed, four repeated the trend seen in the
microarray analysis. For the two genes that did not, the primers
appeared to amplify with similar efficiencies to other primers
(data not shown). Overall, the qRT-PCR data support the fact
that the genes identified in our microarray are changed in
expression in the absence of IclR, based on a different method.
We then tested the same set of gene homologs on RNA iso-
FIG. 6. IL-1 release and cytotoxicity in murine bone marrow-derived
macrophages infected with LVS iclR. Infections were carried out at an
MOI of 500 for wild-type LVS, LVS iclR, and LVSiclR plus IclR
(complementation). (A) IL-1 was quantified via ELISA, and (B) cyto-
toxicity was quantified via the ToxiLight bioassay (Lonza), both at 24 h
postinfection. Graphs are representative of at least three separate exper-
iments, with duplicate or triplicate wells for each strain per experiment.
No differences were significant by any strain comparison based on Stu-
dent’s t test.
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lated from wild-type U112 and the U112 iclR transposon mu-
tant (Fig. 7B). Quantitative RT-PCR first verified that iclR
transcript levels were substantially lower in the transposon
mutant. Overall, the six selected genes appeared to be changed
to similar extents as their LVS homologs, suggesting a similar
set of genes are affected by IclR in U112. These analyses did
not account for any additional genes affected by the U112 IclR
that were not affected by the LVS IclR as detected by microar-
ray. Furthermore, these analyses alone are not sufficient to
extrapolate any correlations in terms of IclR function or to
determine which of the IclR-affected genes are likewise im-
pacted at the protein or functional level.
Effects of IclR on antibiotic resistance. Other IclR family
proteins are known to be involved in the regulation of multi-
drug efflux pumps (39). In all three F. tularensis subspecies, iclR
is located near ORFs encoding hypothetical proteins that have
homology to the EmrA multidrug efflux pump. In LVS, the two
ORFs encoding proteins with EmrA homology that are found
upstream of iclR were not changed in expression as determined
by our microarray analysis. Nevertheless, the microarray data
for LVS iclR showed increased expression of a gene encoding
a protein with homology to organic solvent tolerance proteins,
suggesting that IclR may be involved in repression of some
genes involved in drug efflux. Organic solvent tolerance is often
associated with multidrug efflux pumps, most notably in Esch-
erichia coli and Pseudomonas putida (42). Furthermore, our
BLASTp analyses of hypothetical genes that appeared in the
LVS iclR microarray gene list also revealed proteins with
homology to other transporter proteins. To determine whether
iclR is involved in drug efflux, we performed disc diffusion
assays using a panel of antibiotics. Antibiotics selected for
analysis were chosen as representative of several classes of
antibiotics targeting cell wall synthesis, protein synthesis, nu-
FIG. 7. Transcript levels of genes found significantly changed in mi-
croarray analysis comparing LVS and LVS iclR. RNA was isolated from
wild-type F. tularensis subsp. holarctica LVS and LVSiclR (A) or wild-
type F. tularensis subsp. novicida U112 and a U112 iclR transposon mutant
(B) and used in qRT-PCR analysis for several genes that were significantly
changed in the microarray. Data are presented as the relative log change
for the wild type versus the respective iclR mutant after normalization to
gyrA. The graphs are representative of two or three experiments.




change Description or annotation (BLASTp)
a




FTT0748 34.57 iclR Intact Intact Intact
FTT0980 5.02 Hypothetical protein (aminotransferase class II) Intact Intact Intact
FTT0987 2.84 Hypothetical protein (membrane protein of unknown function) Pseudogene Pseudogene Intact
FTL_1506 2.82 Short-chain dehydrogenase (reductase family protein) Intact Pseudogene Intact
FTT1082 2.64 T1082 protein Intact Intact Intact
FTL_0388/FTT0885 2.63/2.18 Cation transporter (cobalt zinc cadmium cation transporter) Pseudogene Intact Intact
FTL_1256 2.62 Pseudogene (carbon-nitrogen hydrolase family protein) Pseudogene Pseudogene Intact
FTL_1507 2.57 3-Oxoacyl-acyl-carrier protein	 reductase Intact Pseudogene Intact
FTT1081 2.53 Hypothetical protein (hemolysin-type binding protein) Intact Intact Absent
FTT1507 2.37 Hypothetical protein (thymosin beta-4 family protein) Intact Absent Intact
FTL_1122 2.19 Hypothetical membrane protein Intact Pseudogene Absent





FTT0389 2.16 Acetyltransferase Intactc Intactc Intactc
FTT0203 1.97 Bifunctional purine biosynthesis protein (purH) Intact Intact Intact
Upregulated
FTL_1373/FTT0741 4.28/6.40 Organic solvent tolerance protein Pseudogene Pseudogene Intact
FTT1555 1.93 RNase III (rnc) Intact Intact Intact
FTT1554 1.88 tRNA pseudouridine synthetase B (truB) Intact Intact Intact
FTT0554 1.59 Hypothetical protein Intact Intact Intact
a Annotation based on the microarray; BLASTp results (shown in parentheses), when included, provided additional information.
b Following alignments, genes were designated as intact, absent, or a pseudogene (introduced stop codon and two shorter predicted ORFs); genes those without such
designations are discussed in the text.
c Possible alternative start site (see text for details).
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cleic acid synthesis, and cell membrane integrity. There was no
difference in antibiotic sensitivity between wild-type LVS and
LVS iclR using this method (Fig. 8).
DISCUSSION
Herein we investigated the contribution of the putative tran-
scriptional regulator IclR to F. tularensis pathogenicity. In this
study, we found that the LVS iclR was not attenuated for
intracellular replication in J774A.1 macrophage-like cells,
TC-1 epithelial cells, or bone marrow-derived macrophages.
Similarly, SchuS4 iclR was not attenuated for replication in
J774A.1 cells. These data are consistent with published data by
Weiss et al. for the F. tularensis subsp. novicida U112 iclR
deletion mutant strain in bone marrow-derived macrophages
(53).
Compared to wild-type LVS, LVS iclR did not impact
IL-1 induction or cytotoxicity of infected cells; these results
are different from those of the published F. tularensis subsp.
novicida studies (53). It is important to note that the methods
used for these analyses were different between the two studies.
The levels of IL-1 that we reported in this study are near but
not below the limit of detection for the ELISA. The fact that
the levels of IL-1 induced were low is consistent with other
studies providing evidence that LVS suppresses the inflamma-
tory response (26, 50). Furthermore, Weiss et al. used pre-
stimulated bone marrow-derived macrophages, whereas we
used naïve bone marrow-derived macrophages. Macrophages
pretreated with LPS or heat-killed F. tularensis subp. novicida
as well as thioglycolate-elicited macrophages produce higher
levels of IL-1 in response to infection (11, 12, 36, 52). An-
other possibility is that there are strain-specific differences in
the role of IclR, as evidenced by the results of the in vivo
studies discussed below.
Unlike the F. tularensis subsp. novicida iclR deletion mutant,
neither LVS iclR nor SchuS4 iclR was attenuated in mice
following i.n. inoculation. There were differences in the exper-
imental design between our studies and the F. tularensis subsp.
novicida study. We initially inoculated mice i.n. and monitored
the lungs, liver, and spleen over several days postinfection.
Weiss et al. used s.c. and i.p. inoculations in competition assays
and examined the spleen at 2 days postinfection. It is possible
that the inoculation route may have an impact on the impor-
tance of IclR on establishing infection. To address the possi-
bility that the phenotype is route specific, we performed a
reciprocal analysis by evaluating the virulence of LVS and
U112 iclR mutants in i.d. and i.n. infection models, respec-
tively. The results confirmed that the Francisella virulence-
specific properties of IclR are restricted to F. tularensis subsp.
novicida.
It is not clear why IclR is required for virulence in U112 but
not LVS and SchuS4. Based on our microarray analysis, the
subspecies-specific sequence differences among IclR-affected
genes could contribute to the functional differences we ob-
served for IclR between subspecies. Many of the genes are
intact in U112, but in LVS and/or SchuS4 the homologous
gene(s) is a pseudogene or displayed significant sequence vari-
ation (e.g., two large deletions in FTT0715/FTL_1521). The
virulent subspecies of F. tularensis are noted for their genome
decay, as characterized by smaller genomes as well as increased
numbers of pseudogenes, transposases, and gene rearrange-
ments (51). Genome-wide analyses of Francisella strains sup-
port this idea, and many of the genes changed in LVS iclR
that we identified to be pseudogenes correlate with those
found in other studies (7, 44). It is possible that IclR in F.
tularensis subsp. novicida exerts its effects on genes that are
intact, whereas in LVS and SchuS4, IclR affects genes that are
similar to those in F. tularensis subsp. novicida but because of
disruptions or changes to the ORFs, many of these genes are
transcribed but do not encode functional proteins. We must
also consider that there are two genes in the list that are absent
in U112 that are present in LVS and SchuS4, and the absence
of a gene affected by IclR in F. tularensis subsp. novicida could
also contribute to the different phenotypes. Overall, analysis of
the genes identified in our microarray suggests that the major-
ity of genes affected by IclR have differences in sequence
between the three subspecies and that this variation could
contribute to the phenotypic disparities observed.
Taken together, our data suggest that IclR contributes to the
virulence of U112 but not to that of LVS or SchuS4, highlight-
ing the fact that there are significant differences among these
strains. Another example of differences among strains is seen
in the conserved acid phosphatases, AcpA, AcpB, and AcpC.
These proteins have been shown to be required for the viru-
lence of F. tularensis subsp. novicida, but not for the virulence
of SchuS4 (8, 38). Even though IclR may not play a major role
in SchuS4 or LVS virulence, there are other potential roles
that IclR could have as a functional transcriptional regulator.
Quite a few of the microarray-identified genes encode hypo-
thetical proteins, but there are others that encode proteins
with known functions or are homologous to proteins with
known functions. Investigation into these proteins may provide
additional understanding of the function of IclR in F. tularen-
sis. For example, in Pseudomonas putida, the IclR family pro-
teins TtgT and TtgV regulate operons encoding genes that
form efflux pumps for organic solvent extrusion (16, 22). Al-
though our antibiotic sensitivity assays showed no role for IclR
in drug efflux by LVS, we cannot rule out the involvement of
IclR in the regulation of a system specific for organic solvent
efflux or the role of IclR in drug efflux in other F. tularensis
subspecies. Finally, direct comparison of the complete tran-
FIG. 8. Antibiotic sensitivity of LVS iclR. Wild-type LVS and
LVS iclR were grown to mid-log phase, bacteria were spread on
chocolate agar, and an antibiotic-containing paper disc was added to
the center. Bacteria were grown for 36 h, and the diameter of the zone
of inhibition was measured. The experiment was performed in tripli-
cate, and the averages and standard deviations were calculated.
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scriptional profiles of F. tularensis subsp. novicida, F. tularensis
subsp. tularensis, and F. tularensis subsp. holarctica iclR dele-
tion strains might reveal some clues to the properties that are
responsible for the phenotypic differences. Unfortunately, the
currently available microarrays do not contain targets for genes
found exclusively in F. tularensis subsp. novicida.
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